The new DR-70 immunoassay detects cancer of the gastrointestinal tract: A validation study

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 9, 2004, Pages 983-987

  Kerber, A ^a   Trojan, J ^a   Herrlinger, K ^a   Zgouras, D ^a   Caspary, W F ^a   Braden, B ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN DEGRADATION PRODUCT;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DIGESTIVE SYSTEM CANCER; DR 70 IMMUNOASSAY; ESOPHAGUS CANCER; FEMALE; FIBRINOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 9944260845     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02212.x     Document Type: Article

References (11)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
2. Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000; 18: 600-8.
3. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395.
4. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-9.
5. Ossowski L, Quigley JP, Kellermann GM, et al. Fibrinolysis associated with oncogenic transformation. J Exp Med 1973; 138: 1056-1064.
6. Mulcahy HE, Duffy MJ, Gibbons D, et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 344: 583-4.
7. Wu D, Zhou X, Yang G, et al. Clinical performance of the AMDL DR-70 Immunassay kit for cancer detection. J Immunoassay 1998; 19: 63-72.
8. Okholm M, Iversen LH, Thorlacius-Ussing O, Ejlersen E, Boesby S. Fibrin and fibrinogen degradation products in plasma of patients with colorectal adenocarcinoma. Dis Colon Rectum 1996; 39: 1102-6.
9. Gerner C, Steinkellner W, Holzmann K, et al. Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thromb Haemost 2001; 85: 494-501.
10. Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today 1998; 28: 373-8.
11. Blackwell K, Hurwitz H, Lieberman G, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004; 101: 77-82.